Status:
ACTIVE_NOT_RECRUITING
Role of ROS and cAMP-PKA Biomarkers in ADPKD
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
United States Department of Defense
Conditions:
Autosomal Dominant Polycystic Kidney Disease
Eligibility:
All Genders
15-70 years
Brief Summary
The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
Detailed Description
Individuals with ADPKD are born with normal renal function that is preserved for several decades. By the time the GFR starts to decline, most of the kidneys have been replaced by cysts. The median age...
Eligibility Criteria
Inclusion
- Male and female subjects 15 - 70 years of age
- Previous diagnosis of ADPKD (based on Ravine et al. criteria)
- Class 1 A-E according to imaging classification
- estimated GFR\> 45 mL/min/1.73 m2 (CKD-EPI)
- Ability to provide written, informed consent
Exclusion
- Class 2, according to imaging classification
- A concomitant systemic disease affecting the kidney
- Diabetes mellitus
- Predicted urine protein excretion in \>1 g/24 hrs. and or abnormal urinalysis
- Use of antioxidants, i.e., vitamins, Nrf2 activators
- Patients who are part of an interventional study or taking tolvaptan
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07217158
Start Date
July 1 2023
End Date
June 30 2027
Last Update
October 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905